Federico Abascal

Nov 1, 2024 | medrxiv.org | Matthew Neville |Andrew Lawson |Rashesh Sanghvi |Federico Abascal

I.M., M.R.S., and P.J.C. are co-founders, shareholders, and consultants for Quotient Therapeutics Ltd. R.E.A. is an employee of Quotient Therapeutics Ltd. M.E.H. is a co-founder of, consultant to and holds shares in Congenica, a genetics diagnostic company. This research is supported by core funding from Wellcome Trust. R.R. is funded by Cancer Research UK (C66259/A27114) and Medical Research Council (MR/W025353/1).

Oct 26, 2023 | nature.com | Elke Rodríguez |Andrew Lawson |Federico Abascal |Philip Jones |Iñigo Martincorena |Peter Campbell

AbstractSomatic mutations are hypothesized to play a role in many non-neoplastic diseases. We performed whole-exome sequencing of 1,182 microbiopsies dissected from lesional and nonlesional epidermis from 111 patients with psoriasis to search for evidence that somatic mutations in keratinocytes may influence the disease process. Lesional skin remained highly polyclonal, showing no evidence of large-scale spread of clones carrying potentially pathogenic mutations.